Drug intelligence / Profile preview

Kuaishukang

Development stage: Unknown
Lead developer: Baiyiyuan BioTech
Administration: Topical

Overview

Kuaishukang is an alginate-based wound dressing developed by Baiyiyuan BioTech. As a medical device, it is designed for the management of acute and chronic wounds, particularly those with moderate to heavy exudate. Upon contact with wound fluid, the alginate fibers transform into a soft, hydrophilic gel that conforms to the wound bed, maintaining a moist environment essential for optimal healing and facilitating autolytic debridement. This mechanism helps protect the wound from contamination while supporting tissue regeneration.

Brand names: Kuaishukang快舒康
Other names: Alginate wound dressing藻酸盐敷料

Beyond the preview

Go deeper on Kuaishukang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kuaishukang.

Explore the full profile